Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Open-label Active-controlled Study to Assess the Safety, Tolerability, and Efficacy of Afabicin IV/Oral in the Treatment of Patients With Bone or Joint Infection Due to Staphylococcus

NCT03723551 is registered in ClinicalTrials.gov with Debiopharm International SA as lead sponsor.

NCT NCT03723551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03723551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Open-label Active-controlled Study to Assess the Safety, Tolerability, and Efficacy of Afabicin IV/Oral in the Treatment of Patients With Bone or Joint Infection Due to Staphylococcus
Lead sponsor
Debiopharm International SA
Phase
Phase 2
Overall status
Terminated
Start date
February 20, 2019
Completion date
April 23, 2025
Enrollment
67 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

bone or joint infection